KRON – kronos bio, inc. (US:NASDAQ)
Stock Stats
News
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors [Yahoo! Finance]
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio, Inc. (NASDAQ: KRON) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $6.00 price target on the stock.
Form 8-K Kronos Bio, Inc. For: Nov 04
Form S-3 Kronos Bio, Inc.
Form 4 Kronos Bio, Inc. For: Oct 15 Filed by: Frisbee Allison
Form 4 Kronos Bio, Inc. For: Oct 15 Filed by: Lin Charles Y
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.